A recent study reported that allosteric inhibition of SHP2 leads to direct and selective depletion of pro-tumorigenic M2 macrophages and promotes antitumor immunity, suggesting a therapeutic approach for Ras-driven cancers (Quintana et al., 2020). The gene discussed is PTPN11; the disease is cancer.